X0609 4 2026-03-16 0 0001356576 SUPERNUS PHARMACEUTICALS, INC. SUPN 0001539215 Bhatt Padmanabh P. C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE ROCKVILLE MD 20850 0 1 0 0 Sr. VP of IP, CSO 1 Common Stock 2026-03-16 4 M 0 22750 36.75 A 39794 D Common Stock 2026-03-16 4 M 0 4250 29.61 A 44044 D Common Stock 2026-03-16 4 M 0 18000 32.20 A 62044 D Common Stock 2026-03-16 4 M 0 5000 27.94 A 67044 D Common Stock 2026-03-16 4 S 0 34114 50.18 D 32930 D Common Stock 2026-03-16 4 S 0 15886 50.49 D 17044 D Common Stock 2026-03-17 4 M 0 22750 39.40 A 39794 D Common Stock 2026-03-17 4 M 0 12250 36.75 A 52044 D Common Stock 2026-03-17 4 M 0 15000 38.60 A 67044 D Common Stock 2026-03-17 4 S 0 27710 49.95 D 39334 D Common Stock 2026-03-17 4 S 0 22290 50.73 D 17044 D Common Stock 2026-03-18 4 M 0 7250 39.40 A 24294 D Common Stock 2026-03-18 4 S 0 6838 49.55 D 17456 D Common Stock 2026-03-18 4 S 0 412 50.48 D 17044 D Employee Stock Option (Right to Buy) 36.75 2026-03-16 4 M 0 22750 0 D 2029-02-22 Common Stock 22750 12250 D Employee Stock Option (Right to Buy) 29.61 2026-03-16 4 M 0 4250 0 D 2031-02-19 Common Stock 4250 0 D Employee Stock Option (Right to Buy) 32.20 2026-03-16 4 M 0 18000 0 D 2032-02-22 Common Stock 18000 0 D Employee Stock Option (Right to Buy) 27.94 2026-03-16 4 M 0 5000 0 D 2034-02-22 Common Stock 5000 15000 D Employee Stock Option (Right to Buy) 39.40 2026-03-17 4 M 0 22750 0 D 2028-02-14 Common Stock 22750 7250 D Employee Stock Option (Right to Buy) 36.75 2026-03-17 4 M 0 12250 0 D 2029-02-22 Common Stock 12250 0 D Employee Stock Option (Right to Buy) 38.60 2026-03-17 4 M 0 15000 0 D 2033-02-23 Common Stock 15000 5000 D Employee Stock Option (Right to Buy) 39.40 2026-03-18 4 M 0 7250 0 D 2028-02-14 Common Stock 7250 0 D Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.34 to $50.34. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.77. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.40 to $50.39. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.40 to $51.15. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.40 to $49.99. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The option vested in four equal annual installments beginning on February 22, 2020. The option vested in four equal annual installments beginning on February 19, 2022. The option vests in four equal annual installments beginning on February 22, 2023. The option vests in four equal annual installments beginning on February 22, 2025. The option vested in four equal annual installments beginning on February 14, 2019. The option vests in four equal annual installments beginning on February 23, 2024. /s/ Timothy C. Dec, as attorney-in-fact 2026-03-18